Expression of rhEPO-L-Fc fusion protein and analysis of its bioactivity and pharmacokinetics / 生物工程学报
Chinese Journal of Biotechnology
;
(12): 1874-1879, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-302898
ABSTRACT
To prolong serum half-life of human Erythropoietin for better efficacy, a new form of recombinant human erythropoietin (rhEpo-L-Fc) was generated by fusion of a full length human erythropoietin gene and the Fc fragment of human IgG1 with flexible linker sequence. The fusion gene rhEPO-L-Fc was constructed by PCR, then inserted into expression vector pOptiVEC-TOPO, and expressed in Chinese Hamster Ovary cells deficient in the DHFR enzyme(CHO-dhfr-). The chimeric protein was purified by Protein A affinity chromatography, showed expected molecular weight and demonstrated a similar bioactivity compared to that of the native recombinant human erythropoietin (rhEPO) in an EPO-dependent cell-based assay. In vivo pharmacokinetic studies showed that the rhEPO-L-Fc had an elimination half-life of 27 h. In vivo efficacy studies showed that a single dose administration of rhEPO-L-Fc in rats increased the reticulocyte number in the peripheral blood significantly. These results demonstrated that the new engineered rhEPO-L-Fc may become alternative therapeutic approach to extend the half-time of rhEPO to treat anemia.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recombinant Fusion Proteins
/
Recombinant Proteins
/
Immunoglobulin Fc Fragments
/
Pharmacokinetics
/
Chemistry
/
Cricetulus
/
Erythropoietin
/
CHO Cells
/
Rats, Sprague-Dawley
/
Genetics
Limits:
Animals
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Biotechnology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS